fingolimod ratiopharm 0.25 mg kapseli, kova
ratiopharm gmbh - fingolimod hydrochloride - kapseli, kova - 0.25 mg - fingolimodi
fingolimod ratiopharm 0.5 mg kapseli, kova
ratiopharm gmbh - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod zentiva 0.5 mg kapseli, kova
zentiva, k.s. - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod orion 0.5 mg kapseli, kova
orion corporation - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod mylan
mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kanssa vaikea ja nopeasti etenevä relapsoiva-remittoiva multippeliskleroosi on määritelty 2 tai enemmän invaliditeettiin sairauden pahenemisvaiheita on yksi vuosi, ja 1 tai enemmän gadolinium parantaa vaurioita aivojen mri tai merkittävä kasvu t2-leesio kuormitus verrattuna aiempaan tuoreeseen magneettikuvaukseen.
fingolimod mylan
mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
inzolfi 0.5 mg kapseli, kova
sandoz a/s - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
golpimec 0.5 mg kapseli, kova
neuraxpharm sweden ab - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
gaxenim 0.5 mg kapseli, kova
bausch health ireland limited - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod krka 0.5 mg kapseli, kova
krka, d.d., novo mesto - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi